BioSpace News Archive

Endoceutics Inc., Université Laval, and CHU de Québec-Université Laval are pleased to announce that they have reached an agreement to resolve all their disputes with respect to economic benefits deriving from research.

Mirum Pharmaceuticals announced today that data from three of its programs will be presented at the International Liver Congress™ 2019, occurring in Vienna, Austria, from April 10-14, 2019, at the Reed Messe Wien Exhibition & Congress Center.

Tap Native, the Web’s leading health focused native ad platform and traffic exchange, has announced the exit of its beta status and the official launch of its health only traffic exchange designed for health, wellness and medical publishers.

According to new data released today, the Express Scripts SafeGuardRx® offering – the company’s first-to-market value-based programs for employers and health plans – improved patient engagement and increased medication adherence while reducing costs for some of the nation’s costliest therapies.

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data highlights from six presentations showcasing technology advances in the company’s antibody-drug conjugate (ADC) platform and an immuno-oncology program at the American Association for Cancer Research (AACR) Annual Meeting 2019 being held March 29-April 3, 2019 in Atlanta.

Axcella Health announced a late-breaker poster presentation for their novel endogenous metabolic modulator composition, AXA1665 in subjects with mild and moderate hepatic insufficiency.

Vaxart, Inc. announced the completion of dosing of the lead-in cohort in the Phase 1b bivalent norovirus vaccine clinical trial with its oral norovirus GII.4 vaccine.

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced the initiation of a collaboration with Florida International University (FIU) to create computational models of the company’s lantibiotic compounds interacting with bacterial membranes and Lipid II, the target of Oragenics’ compounds with the ultimate goal of expanding the lantibiotic pipeline.

Includes oral presentation on data from ongoing Phase I study with BAY 2731954 (formerly LOXO-195), a tropomyosin receptor kinase (TRK) inhibitor that is currently being investigated in patients who have progressed or were intolerant to prior TRK inhibitors

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its 2018 Registration Document has been filed with the French “Autorité des Marchés Financiers” (AMF) on 26 March 2019 and registered under the number D.19-0205.